Best Life Sciences Companies in Houston, United States
The 240 best Life Sciences companies in Houston, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: EndoQuest Robotics.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Houston
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | EndoQuest Robotics Developer of a robotic system for endoluminal and single-incision surgery 53Innovation top 15%Patents top 22%Funding top 26%Moat top 41% All 9 signals ▾Innovationtop 15% Patentstop 22% Fundingtop 26% Moattop 41% Talentbottom 49% Techbottom 43% Newsbottom 42% Globalbottom 40% Marketbottom 31% Innovation: 135 patents (top 15% of patent-holders) · 131 filings since 2022 vs 4 in 2017-21 Patents: 135 patents matched (strict assignee match) · 131 filings since 2022 vs 4 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $202M | 13 mo ago | 21 | Kurt Azarbarzin CEO | ExpressionEnginePHPVimeo+18 | 135 patents Robotic surgical system control, instrumentation, and safety components for minimally invasive procedures | — |
| 2 | Marker Therapeutics Developer of T-cell based therapeutics for cancer treatment 42Talent top 15%Funding top 18%News top 47%Tech top 50% All 9 signals ▾Talenttop 15% Fundingtop 18% Newstop 47% Techtop 50% Moattop 50% Marketbottom 43% Growthbottom 40% Globalbottom 32% Fin. healthbottom 29% Talent: Analyst team rating 5/5 Funding: Raised $154M across 23 rounds · 23 rounds over 10 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $154M | 9 mo ago | 67 | — | DrupalApple iCloud MailMicrosoft 365+22 | — | — |
| 3 | AlloVir Developer of T-cell therapies to treat infectious diseases | $151M | 84 mo ago | 97 | David Hallal Co-Founder | — | 8 patents Ex vivo expansion of multivirus-specific T cells for transplant infection prophylaxis | — |
| 4 | Bellicum Developer of T cell therapies for the treatment of cancer and chronic infectious diseases | $138M | 141 mo ago | 108 | — | DrupalApple iCloud MailMicrosoft 365+20 | — | — |
| 5 | CoRegen Developer of a novel cancer therapy targeting Treg cells | $121M | 11 mo ago | — | John Thomas CFO | — | — | — |
| 6 | Procyrion Developing percutaneous mechanical circulatory support for heart failure and cardiorenal syndrome | $114M | 28 mo ago | 28 | Eric Fain President and CEO | — | 100 patents Percutaneous intravascular blood pumps for mechanical circulatory support and perfusion. | — |
| 7 | Alleviant Medical Developer of devices to lift the burden of heart failure | $89M | 15 mo ago | 37 | Jacob Kriegel Md Co-Founder & CMO | BugHerdNode.jsMonaco Editor+23 | — | — |
| 8 | Tvardi Developer of small molecule based therapeutics for cancer treatment | $83M | 60 mo ago | 15 | — | WordPressDrupalMySQL+24 | — | — |
| 9 | Vivante Health Provider of virtual telehealth platform for digestive care | $78M | 32 mo ago | 20 | Kimon Angelides Founder & CEO | — | — | 1 partnership · 1 award |
| 10 | Allterum Developer of drugs for treating leukemia disease | $66M | 52 mo ago | 2 | — | — | — | — |
| 11 | Medicenna Therapeutics Developer of interleukin-4 Receptor (IL4R) targeted cytokines for cancer | $54M | 25 mo ago | 1 | — | DrupalPHPBootstrap+22 | — | — |
| 12 | Ingeneron Developer of cell-separation technology for regenerative medicine | $51M | 28 mo ago | 30 | — | WordPressMySQLPHP+18 | 80 patents Patents concentrated in chemistry & materials | — |
| 13 | ImmunoGenesis Developer of therapeutic solutions for treating tumors | $44M | 27 mo ago | 14 | Michael Curran Founder | WordPressMySQLPHP+18 | 18 patents Targeted hypoxia‑activated prodrugs and STING agonist combos for cancer immunotherapy | — |
| 14 | DNAtrix Oncolytic virus platform for treating malignant glioma. | $43M | 45 mo ago | 13 | — | — | 81 patents Oncolytic adenovirus gene therapies targeting pediatric brain tumors and immune activation | — |
| 15 | RadioMedix Developer of targeted radiopharmaceuticals for cancer diagnosis and treatment | $40M | 44 mo ago | 26 | Izabela Tworowska Co-Founder & CSO | WordPressMySQLPHP+14 | 65 patents Automated production of lead‑212 radionuclide for targeted alpha‑particle cancer therapy | — |
| 16 | March Biosciences Developer of CAR-T cell therapies for malignancies | $33M | 20 mo ago | — | Max Mamonkin Co-Founder and CSO | — | — | — |
| 17 | Othram Provider of genomic services for forensic labs | $33M | 28 mo ago | 22 | David Mittelman Co-Founder & CEO | Cart FunctionalityShopifyApple iCloud Mail+23 | 8 patents Privacy-preserving genomic data management and molecular metadata handling | — |
| 18 | XCath Developer of endovascular robotics and steerable guidewires 45Innovation top 23%Patents top 26%Funding top 28%Moat top 28% All 7 signals ▾Innovationtop 23% Patentstop 26% Fundingtop 28% Moattop 28% Talentbottom 49% Globalbottom 40% Marketbottom 24% Innovation: 128 patents (top 15% of patent-holders) · 72 filings since 2022 vs 56 in 2017-21 Patents: 128 patents matched (strict assignee match) · 72 filings since 2022 vs 56 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $30M | 3 mo ago | 10 | Eduardo Fonseca CEO | — | 128 patents Patents concentrated in health & consumer products | — |
| 19 | Bivacor Developer of ventricular assist device (VAD) | $28M | 22 mo ago | 29 | — | WordPressMySQLPHP+16 | 45 patents Design and control of ventricular assist blood pumps and heart pump drive systems | 2 job openings |
| 20 | CoRegen Developer of immunotherapeutics for the treatment of cancer | $27M | 13 mo ago | — | Steve Gorlin CEO | — | — | — |
| 21 | Pulmotect Developer of therapeutics against lung infections | $25M | 21 mo ago | 4 | — | — | 21 patents Immunomodulatory therapeutics targeting adaptive immunity for asthma and viral infection treatment | — |
| 22 | Nanospectra Developer of nanoparticle-based cancer treatment for solid tumors | $25M | 39 mo ago | 9 | — | WordPressMySQLPHP+17 | — | — |
| 23 | CNS Pharmaceuticals Developer of treatments for primary and metastatic cancers in the brain and central nervous system 42Funding top 23%News top 23%Growth top 25%Talent top 43% All 7 signals ▾Fundingtop 23% Newstop 23% Growthtop 25% Talenttop 43% Techbottom 45% Globalbottom 43% Marketbottom 19% Funding: Raised $22.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 6 BI events in 12 mo (of 33 tracked, 7 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 42/100 | $23M | 1 mo ago | 5 | John Climaco CEO | WordPressMySQLPHP+15 | — | 1 job opening |
| 24 | Invectys Developer of immunotherapeutic cancer treatments targeting HLA‑G antigen | $22M | 20 mo ago | 25 | Simon Wain-Hobson Co-Founder & CSO | WordPressMySQLPHP+19 | 4 patents Engineered CAR‑T cell immunotherapy targeting HLA‑G antigen | — |
| 25 | Coya Therapeutics Developer of therapeutics for cell therapy and exosome therapy | $20M | 19 mo ago | 6 | — | WordPressMySQLPHP+14 | — | — |
| 26 | Motif neurotech Developer of minimally invasive bioelectronics for mental health disorders | $19M | 28 mo ago | 7 | Jacob Robinson Co-Founder & CEO | WebflowApple iCloud MailGoogle Workspace+11 | 8 patents Closed-loop neural interfaces using implantable magnetoelectric stimulation and wireless monitoring | 1 partnership |
| 27 | GlycosBio Industrial biotechnology company focusing on development of specialty chemicals and food supplements | $17M | 27 mo ago | 7 | Daniel Monticello Co-Founder | — | 21 patents Lipid-based oil formulations for cosmetics, drug delivery, and latex-compatible industrial applications. | — |
| 28 | Spark Biomedical Developer of wearable neurostimulation technology for drug-free opioid withdrawal treatment 53Patents top 23%Innovation top 26%Funding top 32%Moat top 38% All 10 signals ▾Patentstop 23% Innovationtop 26% Fundingtop 32% Moattop 38% Techtop 40% Growthtop 45% Talentbottom 49% Productbottom 48% Globalbottom 40% Marketbottom 29% Patents: 61 patents matched (strict assignee match) · 55 filings since 2022 vs 6 in 2017-21 Innovation: 61 patents (top 27% of patent-holders) · 55 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $16M | 10 mo ago | 18 18 → 27 (+50%) | Daniel Powell CEO | WebflowMemberStackJava+29 | 61 patents Non‑invasive auricular neurostimulation devices for women's health therapies | 1 award |
| 29 | 7 Hills Pharma Developing integrin agonists to improve immunotherapies for cancer and genetic diseases | $15M | 25 mo ago | 9 | Upendra Marathi President & CEO | Cart FunctionalitySquarespace CommerceSquarespace+13 | — | — |
| 30 | Asylia Therapeutics Developer of medicines for cancer, autoimmune, and infectious diseases | $14M | 14 mo ago | 4 | Richard Jones Co-Founder | — | — | — |
| 31 | Memgen Developer of immunotherapies to treat cancer | $12M | 18 mo ago | 9 | — | — | 72 patents Oncolytic virus and CD40/TLR‑based immunotherapy platforms for cancer and vaccines | — |
| 32 | Amprion Revolutionizing neurodegenerative disease diagnosis with advanced α-synuclein detection technology | $12M | 20 mo ago | 34 34 → 37 (+9%) | Russ Lebovitz CEO | — | 95 patents Protein misfolding detection assays for neurodegenerative disease biomarkers | — |
| 33 | Diakonos Provider of immunotherapeutics for cancer treatment | $11M | 12 mo ago | — | Mike Wicks CEO | WordPressMySQLPHP+18 | — | 1 partnership |
| 34 | Cellvie Developer of cell-derived therapeutics solutions for the treatment of cardiac health, stroke & kidney… | $10M | 9 mo ago | 12 | Alexander Schueller Founder & CEO | BootstrapNginxjQuery+2 | 10 patents Optimizing adoptive cell therapy by generating enhanced immune cell populations for immunotherapy | — |
| 35 | Bio Developer of therapeutics for the treatment of cancer | $10M | 24 mo ago | 10 | — | — | — | — |
| 36 | ImmunoMet Therapeutics Biotech targeting cellular metabolism for novel anti-cancer and anti-fibrosis therapies | $10M | 4 mo ago | 9 | Dean Welsch CEO | — | — | — |
| 37 | PranaX Provider of regenerative science to treat various health conditions | $10M | 4 mo ago | — | Steven Greco Founder & COO | WebflowGSAPLenis+16 | — | — |
| 38 | CrossBridge Bio Developer of Antibody-Drug Conjugate therapeutics | $10M | 19 mo ago | — | Zhiqiang An Co-Founder | WordPressMySQLPHP+19 | — | — |
| 39 | Moleculin Biotech Small molecule drugs for leukemia and other cancers | $10M | 3 mo ago | 19 19 → 22 (+16%) | — | WordPressMySQLPHP+22 | 37 patents Liposomal formulation and lyophilized delivery of annamycin anticancer agent. | — |
| 40 | Stingray Therapeutics Developer of immunotherapeutics for treating cancer | $8M | 15 mo ago | 6 | Sunil Sharma Co-Founder | — | — | — |
| 41 | Prana Thoracic Developer of minimally invasive lung tissue excision tool for lung cancer | $6M | 24 mo ago | 9 | Joanna Nathan Founder & CEO | — | 27 patents Advanced control and sealing systems for minimally invasive thoracic tissue resection. | — |
| 42 | Bayou Surgical Developer of a medical device to improve visualization during surgical procedures | $5M | 7 mo ago | — | Mahmood Khan Co-Founder | — | 25 patents Patents concentrated in health & consumer products | — |
| 43 | Biostate Developer of generative AI based RNAstate research platform to predict future omics states 53AI top 24%Talent top 38%Funding top 40%Patents top 42% All 9 signals ▾AItop 24% Talenttop 38% Fundingtop 40% Patentstop 42% Moattop 42% Innovationtop 45% Techtop 48% Globalbottom 37% Marketbottom 36% AI: Holds AI/ML patents (G06N-family CPC) · Product described with: artificial intelligence, generative ai Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 53/100 | $4M | 13 mo ago | — | Ashwin Gopinath Co-Founder & CTO | Apple iCloud MailGoogle WorkspaceNode.js+15 | 7 patents Patents concentrated in chemistry & materials | — |
| 44 | Vivifi Medical Developer of a minimally-invasive device to treat prostatic hyperplasia male infertility | $4M | 13 mo ago | 2 | Tushar Sharma Founder & CEO | WordPressMySQLPHP+22 | — | — |
| 45 | Ensysce Provider of drug delivery problems with Single-Walled Carbon Nanotubes | $2M | 7 mo ago | 5 | Steven Shafer Co-Founder | WordPress Block EditorWordPressMySQL+21 | — | — |
| 46 | Prana Thoracic Developer of solutions for early intervention in lung cancer | $2M | 14 mo ago | — | Richard Fischel Co-Founder | WebflowjQueryHSTS+9 | 27 patents Patents concentrated in health & consumer products | — |
| 47 | Alaunos Therapeutics Developer of adoptive TCR-T cell therapies for solid tumors. | $850K | 11 mo ago | 34 | — | DrupalPHPAmazon Web Services+20 | — | — |
| 48 | TYBR Health Provider of regenrative medicine for post surgical scarring | $835K | 17 mo ago | 7 | Alex Smith Co-Founder | — | — | 1 launch |
| 49 | Optimvia Developer of enzymes and a cofactor for therapeutic use | $598K | 2 mo ago | — | Keith Kleeman CEO | — | 44 patents Engineered sulfotransferase biocatalysts for tailored heparan sulfate production | — |
| 50 | ReEngage Developer of therapeutics for longevity-related diseases | $365K | 12 mo ago | — | Gottlieb Co-Founder | — | — | 1 partnership |
Top 12 Life Sciences companies in Houston
#1
Public · Houston, Texas · founded 2017 · 5 employees$22.5Mraised▾
Developer of treatments for primary and metastatic cancers in the brain and central nervous system. It offers a pipeline of anti-cancer drug candidates including berubicin that appears to cross the blood brain barrier and kill tumor cells and TPI 287 for glioblastoma multiforme.
- May 2026Series B$22.5M
#2
Public · Houston, Texas · founded 1991 · 67 employees$153.9Mraised▾
Developer of T-cell based therapeutics for cancer treatment. The company's lead product candidates are used against triple-negative breast cancer and ovarian cancer. The company is also developing peptide vaccines for the treatment purpose.
- Aug 2025Grant (prize money)$1.3M
- Jun 2025Grant (prize money)$1.2M
- May 2025Grant (prize money)$2M
- Apr 2025Grant (prize money)$2M
#3
Series C · Houston, Texas · founded 2017 · 10 employees$30Mraised▾
Developer of endovascular robotics and steerable guidewires. The company is developing robotic systems that can enable expert navigation of the body's complex vascular network to treat life-threatening conditions like cerebrovascular disorders.
- Mar 2026Series C$30M
#4
Series D · Houston, Texas · founded 2017 · 21 employees$201.7Mraised▾
Developer of a robotic system for endoluminal and single-incision surgery. The system aims to enable and enhance physician capabilities during surgical procedures. It focuses on eliminating or minimizing external incisions to reduce patient trauma. The goal is to improve patient outcomes, accelerate recovery, and reduce healthcare costs. The system is under development and not for commercial sale.
- May 2025Series D$30.7M
- Dec 2023Series C$42M
- Jun 2021Series C$76.1M
- Apr 2021Series B$69M
#5
Series C · Houston, Texas · founded 2003$121.4Mraised▾
Developer of a novel cancer therapy targeting Treg cells. This therapy aims to eradicate cancer by modifying a single gene in regulatory T cells (Tregs), thereby enabling the immune system to recognize and destroy cancer cells without causing toxicity or inflammation. Pre-clinical trials have shown promising results, and the company is progressing towards human clinical trials. The therapy is designed for outpatient administration, simplifying the treatment process for patients. The technology is based on decades of research in steroid receptor coactivators and is protected by patents.
- Jul 2025Series C$93.4M
- 2024Series B$28M
#6
Public · Houston, Texas · founded 2006 · 19 employees$9.7Mraised▾
Moleculin Biotech is preclinical and clinical-stage company focused on the development of anti-cancer drug candidates and was founded based on the discoveries made at M.D. Anderson Cancer Center. Its lead product candidate Annamycin, an anthracycline molecule will be entering phase IIb trials for the treatment of relapsed or refractory acute myeloid leukemia. Its small molecules pipeline also has WP1066 portfolio 3 candidates which are focused on the modulation of tumor cell signaling mechanisms WP1122 that targets the metabolism of tumors. These candidates are in the IND-filing phase for Cutaneous T-cell lymphoma, Glioblastoma, and Pancreatic cancer.
- Feb 2026Post IPO$8.3M
- Feb 2018Post IPO$9M
- Dec 2017Grant (prize money)$2M
- Oct 2014Conventional Debt$1.4M
#7
Series B · Houston, Texas · founded 2015 · 9 employees$10.2Mraised▾
Biotech targeting cellular metabolism for novel anti-cancer and anti-fibrosis therapies. The company focuses on developing innovative treatments by leveraging the unique metabolic signatures of cancer and immune cells. Their lead molecule targets Oxidative Phosphorylation, aiming to decrease aberrant cell growth and proliferation in targeted cancer cells and fibrosis. They are developing a library of biguanides with the potential for development as novel treatments for cancer and/or diseases of fibrosis. The company is dedicated to advancing science and improving patient outcomes through targeted therapeutic interventions in oncology and fibrosis. They are a clinical stage company.
- Jan 2026Series B$842.2K
- Mar 2017Series B$5M
- Mar 2016Series A$5.2M
#8
Series A · Houston, Texas · founded 2022$10Mraised▾
Provider of regenerative science to treat various health conditions. The company is developing exosomes as anti-aging supplements to establish stem-cell derived exosomes for tissue repair and organ regeneration.
- Jan 2026Series A$17M
- Dec 2023Series A$10M
#9
Series C · Houston, Texas · founded 2017 · 37 employees$89.1Mraised▾
Developer of devices to lift the burden of heart failure. . The company has developed a transcatheter technology intended to decompress the left atrium without a permanent cardiac implant or open surgery. The procedure is performed under fluoroscopy (x-ray) and ultrasound guidance using a minimally-invasive approach and leverages standard interventional cardiology techniques.
- Feb 2025Grant (prize money)$3.9M
- Feb 2025Grant (prize money)$3.9M
- Dec 2024Series C$90.8M
- Sep 2024Grant (prize money)$499.1K
#10
Series A · Houston, Texas · founded 2018 · 18 employees$16.2Mraised▾
Developer of wearable neurostimulation technology for drug-free opioid withdrawal treatment. The company provides non-invasive bioelectric medicine designed to meet critical needs. Their current FDA-cleared neurostimulation solution is for opioid withdrawal. The technology is also evolving into neurological health, hemostasis, and pediatrics.
- Aug 2025Grant (prize money)—
- Apr 2025Series A$15M
- Jun 2024Grant (prize money)$318.9K
- May 2023Series A$16.2M
#11
Seed · Houston, Texas · founded 2020 · 12 employees$10.5Mraised▾
Developer of cell-derived therapeutics solutions for the treatment of cardiac health, stroke & kidney transplantation. The company has developed cell-based medicines by using the therapeutic potential of mitochondria. Its proprietary technology generates chemical energy by using the cell's biochemical reactions that help in the treatment of ischemia-reperfusion injury or reoxygenation injury.
- Sep 2025Seed$5M
- Feb 2023Seed$5.5M
- Jan 2021Seed$5M
- Sep 2020Grant (prize money)—
#12
Series C · Houston, Texas · founded 2019$27.4Mraised▾
Developer of immunotherapeutics for the treatment of cancer. It offers a pipeline of drug candidates based on T regulatory cells and a small molecule inhibitor that blocks the transcriptional activity in cancer cells. It provides drugs for breast, lung, prostate, colorectal, and pancreatic cancer treatment.
- Apr 2025Series C$62.6M
- Jan 2025Series B$20.8M
- Feb 2024Series B$14.5M
- Aug 2022Series B$12.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Houston researches in biotechnology
Houston Methodist and UT Health lead research on nanoparticle-based drug delivery and cancer theranostics, with advancement and breakthrough findings dominating an optimistic stance.
- Houston Methodist14
- The University of Texas Health Science Center at Houston11
- University of Houston3
- Houston Health and Human Services Department2
- Sam Houston State University1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.